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Abstract
The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia
has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine
the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information,
treatment, and response were collected. Prognostic factors inﬂuencing the complete remission (CR) rate and event-free
survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean
± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third
attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third,
and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed
slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the
outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed
for childhood B-ALL.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common
malignancy in children and adolescents, with ~85% of cases
being B-cell precursor ALL (B-ALL). Over the past few
decades, the overall survival rate in children with newly
diagnosed ALL has improved dramatically from ~10% in
the 1960s to almost 90% today [1, 2]. Despite this
remarkable improvement, ~2% patients are refractory to
induction chemotherapy [3], and an additional 10–15% of
ALL patients still experience a relapse [4]. Although
subsequent second complete remission (CR) can be
achieved in most patients [5–8], ~55% of those patients will
relapse again [6, 9]. Those children are generally managed
with intensive chemotherapy, with or without novel agents
to induce a third remission, followed by hematopoietic stem
cell transplant (HSCT) if indicated [10, 11]. Despite the
improvement of outcome in newly diagnosed patients, the
reported event-free survival (EFS) of patients with ﬁrst
relapse of ALL has not changed signiﬁcantly for more than
20 years and remains poor at ~35–50% [5–9, 12, 13]. The
outcome for patients who fail initial induction therapy
(primary induction failure), for those who do not respond to
salvage therapy, and for those who are multiply relapsed is
even worse. Therefore, new strategies are needed to
improve the outcome of these patients.
The Therapeutic Advances in Childhood Leukemia
consortium (TACL) was established in 2004 to develop
innovative therapies through phase I/II clinical trials in
children with incurable leukemia and lymphoma.
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Previously, TACL conducted a retrospective study to
evaluate the remission rates and outcomes for children with
refractory or multiply relapsed (R/R) ALL treated at eight
TACL institutions in the United States (US) from 1995 to
2004 [5]. A CR rate of approximate 40% was identiﬁed in
children who experienced second and subsequent relapse.
Several other studies reported similar outcomes in children
with multiply R/R ALL [10, 11]. The data provided refer-
ence information for clinicians and families to make treat-
ment decisions and serve as a benchmark for the evaluation
of new agents and regimens [5]. However, these studies
may not reﬂect the current practice as treatment patterns and
supportive care measures have changed over the past 10
years.
To provide current and precise estimates of outcome in
children with multiply R/R B-ALL, we performed a more
comprehensive follow-up study using pooled retrospective
data collected from 24 TACL institutions in the US,
Canada, and Australia. The primary objective of the study
was to estimate the CR rate in pediatric patients with mul-
tiply R/R or primary induction failure B-ALL treated
according to the institutional standard of care at participat-
ing centers. The secondary objectives were to estimate the
EFS probabilities in this patient population, and to inves-
tigate patient and disease characteristics that are associated
with these primary and secondary objectives.
Subjects and methods
Patients
The TACL T2014–004 study included patients ≤21 years
with R/R B-ALL who experienced a qualifying treatment
failure at a TACL institution between 2005 and 2013.
Qualifying treatment failures included patients who under-
went salvage treatment for primary induction failure, or
with ≥2 occasions of relapsed disease; or failure to achieve
remission after ﬁrst or more salvage treatment attempt.
Patients meeting the eligibility criteria for this study were
identiﬁed at each participating TACL institution. The
approach for identifying potentially eligible patients inclu-
ded: tumor registries, medical records, hospital billing
records, and internally maintained patient databases to
ensure a complete census of eligible patients. Patient
demographic information and clinical data related to the
initial diagnosis and subsequent treatment failures were
abstracted from the medical record. Collected data included
disease characteristics, chemotherapy regimen, disease
response, and survival until the date of death or end of
follow up at least through 31 December 2014. Data were
entered in the TACL DataLabs Clinical Data Management
System and reviewed centrally. This study was approved by
the institutional review board of each participating
institution.
Deﬁnitions
A salvage treatment attempt was deﬁned as a chemotherapy
treatment plan initiated because of a relapsed or refractory
leukemia. A curative attempt was deﬁned as a treatment
plan with the goal of achieving a CR. To determine whether
a chemotherapy plan was curative or palliative, therapy
regimens were evaluated and classiﬁed by two independent
reviewers. A third reviewer participated when the two
reviewers did not agree. Palliative attempts were excluded
for all analyses that used response as a dependent variable.
The outcomes of these palliative attempts were classiﬁed as
“not evaluable” in analyses using prior treatment response
as an independent variable predictive of subsequent
response.
Response was evaluated using the complete blood count,
bone marrow (BM), and extramedullary disease evaluations
collected at the end of each treatment. Patients were con-
sidered to have achieved a CR if there were ≤5% blasts in
the BM and no evidence of extramedullary disease. Relapse
referred to leukemia recurrence in the BM, central nervous
system (CNS), or other extramedullary sites following a
CR. CNS leukemia was deﬁned as CNS3 disease (≥5/µl
WBCs and positive for blasts, or clinical signs of CNS
leukemia). Medullary relapse was deﬁned as >5% blasts in
the BM. Isolated extramedullary relapse was deﬁned as
≤5% blasts in the BM and evidence of disease in CNS,
testicular, or other extramedullary sites. Combined relapse
was deﬁned as >5% blasts in the BM and evidence of
extramedullary leukemia. Refractory disease was deﬁned as
failure to achieve CR after one course of curative che-
motherapy. Primary induction failure was deﬁned as failure
to achieve CR after one course of induction chemotherapy
for de novo ALL. Patients who had peripheral blasts ≥25%
by morphology without BM assessments were designated to
have relapse or refractory disease. Induction death was
deﬁned as death within 30 days from the initiation of sys-
temic salvage chemotherapy.
The duration of prior remission in patients achieving CR
was deﬁned as the time between relapse date and the date of
the previous CR. EFS was measured from the time of
remission conﬁrmation, to the date of relapse or death from
any cause, or was censored at the earliest of the date of last
follow up or 31 December 2014.
Statistical methods
Response and EFS analyses used salvage attempt as the unit
of analysis. Attempts were excluded from these analyses if
data were insufﬁcient to determine outcome, if the treatment
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was judged as palliative, or if the attempt was prior to the
patient being ﬁrst seen at the TACL institution. The latter
exclusion was to eliminate selection bias of treatment
attempts that were more likely to be successful, as patients
with unsuccessful treatment attempts (e.g., resulting in
death) would be less likely to present at a TACL institution.
Univariable and multivariable logistic regression was
used to analyze reinduction failure rates at the ﬁrst and later
salvage attempts. Independent variables included salvage
treatment attempt number, prior remission duration,
National Cancer Institute (NCI) risk criteria [14] at time of
initial diagnosis, extramedullary and BM status at the start
of the treatment attempt, and cytogenetics at diagnosis.
Cox regression analysis was used to examine the inﬂuence
of these independent variables on EFS following CR. These
analyses were restricted to salvage treatment attempts where
patients achieved remission at their second or later salvage
attempt. The analysis of CR rate and EFS used salvage
attempts rather than patients as the primary analytic unit, so
that each patient contributed data on one or more attempts. As
in our previous publication [5] the corresponding logistic and
Cox regression analyses, accounting for this inter-patient cor-
relation, gave equivalent results to analyses that ignored this
correlation. Results from the latter analytic method are repor-
ted. The administration of HSCT after salvage was included as
a time-dependent covariate in the Cox regression analysis.
All p-values are two-sided tests, and estimates of relative
risk and relative failure rate are presented with 95% con-
ﬁdence intervals. Statistical computation was performed
using Stata 11 (StataCorp. 2009. Stata Statistical Software:
Release 11. College Station, TX: StataCorp LP).
Results
Analysis cohort
A total of 366 unique patients from 24 TACL institutions
with a total of 940 salvage attempts were enrolled in this
study. The analytic set included 578 ﬁrst and greater salvage
treatment attempts among 325 patients (Fig. 1). Reasons for
exclusion included: no evidence of systemic treatment
(n= 20 attempts); attempts that were administered prior to
the patient’s treatment at a TACL institution (n= 108
attempts); attempts that were determined as palliative
(n= 122 attempts); and attempts that were not evaluable for
response due to incomplete or missing data (n= 112
attempts). Those attempts were not included in the analytic
set, although their information could be used as independent
variables in analysis. The clinical characteristics of the
patients at initial diagnosis are summarized in Table 1.
The majority of salvage attempts were due to BM relapse
(458/578, 79.2%), while 13.5% were due to isolated
extramedullary disease (Supplementary Table S1). BM
status was unclear for the remaining 7.3% of the salvage
attempts for extramedullary disease (Supplementary
Table S1). Due to the complexity of the treatment, the
salvage attempts were grouped into chemotherapy only,
Fig. 1 Consort diagram
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attempts with chemotherapy with a novel agent, and
attempts with chemotherapy with HSCT (Supplementary
Table S2). Fifty-eight salvage attempts (10%) included
novel agent. HSCT was included in 31% salvage attempts.
Response to salvage treatment attempts
Since the majority of multiply R/R disease occurred in the
BM, we focused our analysis of the response rate for
treatment of two and more BM (isolated and combined)
relapses. This comprised 267 unique patients with 458 sal-
vage treatment attempts (Fig. 1). Table 2 summarizes the
number of salvage attempts resulting in CR by whether or
not a previous remission was achieved and the length of the
previous remission at the speciﬁed salvage treatment
attempt. The overall CR rate was 69 ± 3.6% after the ﬁrst
salvage treatment attempt, 51 ± 3.9% after the second sal-
vage attempt, and <40% after the third and subsequent
attempts (Table 2). Among the 25 patients with primary
induction failure, 13 patients (52%) achieved CR after ﬁrst
salvage treatment attempt (Table 2). There were 16 induc-
tion deaths among the 458 curative salvage attempts (3.5%).
The results of the logistic regression for reinduction
failure occurring at the ﬁrst and later salvage attempts are
displayed in Table 3. Salvage attempt number, duration of
previous remission, and NCI risk category at diagnosis were
all signiﬁcant predictors in both univariable and multi-
variable analyses (Table 3). In the multivariable model,
increasing salvage attempt number was associated with
increased risk of reinduction failure (trend p= 0.0001).
Duration of prior remission was inversely correlated with
risk of reinduction failure (trend p= 0.0028). Patients with
a high or unknown NCI risk category at initial diagnosis or
infant ALL were also associated with higher risk of rein-
duction failure compared to patients classiﬁed as NCI
standard risk (p= 0.0322). Neither extramedullary invol-
vement nor BM status (M2 vs. M3) at start of therapy was
associated with reinduction failure in univariable and mul-
tivariable analyses. Unfavorable cytogenetics at diagnosis
was associated with higher risk of reinduction failure
compared to patients having favorable and other cytoge-
netics in univariable analysis (p= 0.0429), but not in
multivariable analysis (p= 0.7991).
Comparing the unadjusted CR rate among patients who
received ≥2 salvage attempts between our study and the
previous TACL study, we identiﬁed an improved CR rate
for patients who received fourth through eighth attempts, in
whom 31% of patients achieved CR (Table 4) vs. 12% in
the prior study (p= 0.014) [5].
2 year EFS for patients achieving CR
Next, we focused on factors that impacted 2 year EFS
among patients with at least two salvage attempts who
subsequently achieved a CR. A total of 286 patients were
identiﬁed who met these criteria. Among patients under-
going ≥2 salvage attempts, 125 attempts (in 108 unique
patients) resulted in CR (Fig. 1). Survival analysis was
completed on this cohort of patients. Kaplan–Meier survival
curves by treatment attempts are provided in Fig. 2.
To investigate the prognostic factors that can impact the
survival after achieving CR, Cox regression univariable and
Table 1 Characteristics at initial diagnosis of patients with ALL who
received at least one salvage attempt (n= 325)
Characteristic Levels Number of
patients
%
Age, years <1 (infants) 28 8.6
1–9 183 56.3
10 and over 113 34.8
Unknown 1 0.3
WBC counts/µL <50,000/µl 189 58.1
50,000/µl and over 89 27.4
Unknown 47 14.5
NCI risk criteria at
diagnosis
Non-infants, standard
risk
114 35.1
Non-infants, high risk 137 42.1
Non-infants, unknown 46 14.2
Infants 28 8.6
Sex Female 133 40.9
Male 192 59.1
Testicular disease Yes 3 0.9
No 189 58.2
N/A 133 40.9
CNS leukemia
(CNS3)
Yes 69 21.2
No 225 69.3
Unknown 31 9.5
Cytogeneticsa
Favorable t(12;21) 10 3.1
Hyperdiploidy (>50
chromosomes)
41 12.6
Unfavorable 11q23 (KMT2A gene)
rearranged
39 12.0
Hypodiploidy (<45
chromosomes)
14 4.3
iAMP21 3 0.9
t(9;22) 20 6.2
Other Normal 103 31.7
t(1;19) 9 2.8
9p abnormality 10 3.1
Other 32 9.8
Unknown 44 13.5
CNS central nervous system, NCI National Cancer Institute
a Main Karyotype presented here; 23 patients had multiple entries
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multivariable analyses were performed and presented in
Table 5. Prior number of salvage attempts was the only
signiﬁcant predictor in the univariable analysis of EFS time
among patients who achieved CR after a second or greater
salvage attempt (p= 0.0323, trend p= 0.0906). However,
in the multivariable analysis, the effect of the salvage
attempt number is attenuated. Duration of previous remis-
sion, NCI risk category, extramedullary involvement,
HSCT post-remission, BM status, and cytogenetics at start
of therapy all failed to reach statistical signiﬁcance in both
univariable and multivariable analysis. In addition, in the
multivariable analysis, a trend of decreasing risk of relapse/
death among patients with longer duration of prior remis-
sion for patients with 18–36 months and at least 36 months
duration of previous remission was seen compared to
patients that achieved a prior remission lasting less than
18 months.
Although minimal residual disease (MRD) data were
available for some salvage attempts (40 attempts), most of
the patients did not have MRD data available. Therefore,
MRD was excluded in the analysis.
Discussion
This is the second retrospective pooled data analysis from
TACL that evaluates the outcome of pediatric patients with
multiply R/R B-ALL treated during a contemporary period.
Efforts were made to include a complete census of eligible
patients from each participating center in order to minimize
patient selection bias. Twenty-four TACL institutions par-
ticipated in the study, representing major pediatric hema-
tology/oncology centers across the US, Canada, and
Australia. The inclusion of 325 patients provided us with
the opportunity to undertake a robust analysis and evaluate
factors that inﬂuenced the remission rate and survival.
Comparison of the current study with the previous TACL
study is not straight forward, since the majority of our
patients had ≥2 occasions of relapses, whereas the previous
study also included patients with ﬁrst relapsed disease [5].
Therefore, not surprisingly, the CR rate among our cohort
after a 2nd treatment attempt is biased as it excludes patients
who had a single treatment failure, achieved remission, and
remained in remission, and slightly less than the reported
CR rate of 81–94% in the literature [5–8]. We observed a
trend of improved response rate for patients who had two or
more salvage attempts in our study when compared to the
results reported by Ko et al. and other published studies
[5, 10, 11]. More importantly, we identiﬁed a signiﬁcantly
higher CR rate among patients who received fourth through
eighth salvage attempts in the current study when compared
to the previous TACL study. Considering the improvement
of the treatment of de novo ALL in recent time periods, one
might assume that remission would be harder to achieve in
these multiply salvaged patients. However, our ﬁnding is
consistent with the previous report from the Children’s
Oncology Group suggesting that post-relapse survival is
independent of initial treatment intensity in children with
ﬁrst relapsed ALL [9]. This observation is also consistent
with the ﬁndings of several genomic studies that indicate
that clones responsible for relapse are often present at
diagnosis or mutated to a resistant phenotype through
intrinsic genomic instability rather than treatment exposures
[15, 16]. We speculate this apparent improvement in CR
rate could be related to intensiﬁcation of salvage che-
motherapy, introduction of novel agents in this patient
population in recent time periods, and better supportive
care. However, the difference could also be attributed to
differences in non-treatment-related features of patients in
these two groups.
As previously published, the number of prior salvage
attempts and duration of previous remission are the prog-
nostic factors contributing to the subsequent CR in children
with multiply relapsed ALL [5, 10, 11]. We found no
compelling association of reinduction failure with either
extramedullary involvement or BM status (M2 vs. M3) at
Table 2 Achievement of CR after treatment of bone marrow disease at reporting TACL institutions (n= 267 unique patients with 458 salvage
attempts)
First salvage attempt Second salvage
attempt
Third salvage attempt Fourth through eighth
salvage attempt
Duration of previous CR Total CR % Total CR % Total CR % Total CR %
CR not achieved 25 13 52 43 17 40 35 11 31 30 9 30
CR < 18 months duration 45 25 55 52 22 42 17 6 35 5 2 40
CR 18–36 months duration 40 32 80 26 18 69 2 1 50 3 1 33
CR > 36 months duration 37 30 81 16 15 94 2 2 100 – – –
Prior CR not evaluable 21 16 76 28 12 43 17 7 41 14 4 29
All patients combined 168 116 69 165 84 51 73 27 37 52 16 31
CR complete remission
2320 W. Sun et al.
start of therapy in univariable or multivariable analyses. Our
study identiﬁed that NCI risk category at diagnosis is a
signiﬁcant independent prognostic factor for remission
induction. This observation was consistent with a non-
signiﬁcant trend observed in the previous TACL publication
[5]. However, after achieving CR, it had no impact in the
survival of these patients. Although several studies have
suggested that cytogenetics at diagnosis was an independent
prognostic factor in children with ALL in ﬁrst relapsed or
primary induction failure [3, 13], the impact of cytogenetics
in children with multiply relapsed ALL was unknown. In
our study, unfavorable cytogenetics was associated with
higher risk of induction failure only in univariable ana-
lysis. There appears to be a trend of lower disease pro-
gression among patients with unfavorable cytogenetics
when CR was achieved after ≥2 salvage attempts in
multivariable analysis in our small cohort. Given the wide
95% conﬁdence interval, further studies is warranted.
Taken together, these data highlight the importance of
understanding the biology in relapsed ALL to identify
Table 3 Summary of logistic regression for reinduction failure for medullary disease at reporting TACL institutions (267 unique patients with
458 salvage attempts)
Response Univariable analysis Multivariable analysis
Variable Variable levels CR Failure OR 95% CI OR 95% CI
Salvage attempt 1 116 52 1.0 – 1.0 –
2 84 81 2.15 1.37–3.36 1.83 1.12–2.99
3 and over 43 82 4.25 2.60–6.96 3.02 1.72–5.31
p-value <0.0001 0.0004
Trend p-value <0.0001 0.0001
Duration of previous
remission (CR)
CR not achieved 48 80 1.39 0.84–2.31 1.20 0.69–2.08
CR achieved,
< 18 m duration
56 67 1.0 – 1.0 –
CR achieved,
18–36 m duration
52 19 0.31 0.16–0.56 0.37 0.19–0.71
CR achieved,
> 36 m duration
48 8 0.14 0.06–0.32 0.19 0.08–0.46
Not evaluable for
response
39 41 0.88 0.50–1.54 0.70 0.37–1.29
p-value <0.0001 <0.0001
Trend p-value 0.0021 0.0028
NCI risk category at
diagnosis
Non-infants,
standard risk
110 63 1.0 – 1.0 –
Non-infants, high
risk
100 103 1.80 1.19–2.72 1.62 1.03–2.56
Non-infants,
unknown
23 31 2.35 1.26–4.38 1.80 0.90–3.60
Infants 10 18 3.14 1.37–7.23 3.06 1.25–7.51
p-value 0.0020 0.0322
Extramedullary
involvement at start of
therapy
No 194 171 1.0 – 1.0 –
Yes 49 44 1.02 0.64–1.61 1.21 0.73–2.01
p-value 0.9364 0.4499
BM status at start of
therapy
M2 39 35 1.0 – 1.0 –
M3 204 180 0.98 0.59–1.62 1.45 0.83–2.54
p-value 0.9469 0.1916
Cytogenetics Favorable 49 29 1.0 – 1.0 –
Unfavorable 47 59 2.12 1.17–3.86 1.2 0.59–2.45
Other 147 127 1.46 0.87–2.45 1.0 0.55–1.83
p-value 0.0429 0.7991
BM bone marrow, CI conﬁdence interval, CR complete remission, NCI National Cancer Institute, OR odds ratio. The bold values are the p-values
with statstical signiﬁcance (< 0.05)
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targets for novel therapies that can result in more sus-
tained CR.
Few studies have evaluated survival in patients who
achieved CR3 and beyond. Previous studies reported a
23–31% EFS in patients achieving CR3 [4, 11, 12]. In our
analysis, we found an improved 2 year EFS for patients who
achieved a CR3 (41% ± 5.6%). With small patient numbers,
we found no compelling advantage for HSCT in patients
who achieved CR after ≥2 salvage attempts. Furthermore,
a 2 year EFS of 27 ± 13% was seen in patients who
had ≥4 salvage attempts, a slight improvement from the
previous TACL study, although the number of patients are
very small. Of note, a total of 61 salvage attempts were
administered to 16 patients as their fourth eighth attempts.
Among the 61 salvage attempts, only ﬁve (8%) were CD19
chimeric antigen receptor (CAR) T cell therapy. Therefore,
the improved CR rate among this group could not be solely
explained by the highly effective CD19 CAR T cell
immunotherapy. However, it is possible this treatment could
have resulted in deeper and more sustained CR and have
inﬂuenced the EFS in these 16 patients who experienced
ﬁve or more prior treatment failures.
Overall, compared to previous studies, our data demon-
strated that in the contemporary era, more effective reinduc-
tion therapy resulted in a trend of higher CR rates, more
sustained remissions and improved survival. Despite these
improvements, the majority of patients in our cohort died
from their disease. Therefore, new approaches are still needed
to improve outcomes. The results from our data provide
important reference background information for evaluating
CR rates in future early phase clinical trial designs for B-ALL,
especially with respect to the composition of patient char-
acteristics in those new agent trials which typically included
multiply relapsed/refractory patients. However, it will always
be important to consider the limitations of historical data
when using them as reference in clinical trials because ret-
rospective clinical data are not equivalent to clinical trial data.
Other limitations of our analysis included, the lack of data
regarding organ function, performance status, other co-mor-
bidities, and enrollment in investigational studies. Treatment-
related adverse events and therapy modiﬁcations due to
toxicity were not collected. Only a few patients had MRD
data available; therefore, the impact of MRD in the outcome
is unknown. Out of the 325 patients, only a small number of
patients received CD19 or CD22 directed immunotherapy
(blinatumomab, n= 7; CD19 CAR T cell, n= 11; inotuzu-
mab, n= 1) [17–19]. Therefore, our analysis reﬂects the
treatment outcome prior to the CD19 directed immunotherapy
era. It will be interesting to see whether the introduction of
new promising agents such as blinatumomab, inotuzumab,
and CD19 CAR T cell therapy will change the long-term
outcome in these patients.
In conclusion, this is the largest retrospective study to
date of the outcome of children with multiply R/R B-ALL
receiving contemporary treatment across North America
and Australia, and demonstrated a trend of improvement in
CR rate and survival compared to the previous TACL study.
Table 4 Comparison of unadjusted CR rates of patients with medullary relapsed/refractory ALL between two sequential TACL studies
Number of salvage attempt CR rate (SE)
[95% conﬁdence interval]
Difference (Sun–Ko)
(SE)
(testing proportion)
1995–2004 (Ko et al.) [5] 2005–2013 (Sun et al.)
Second salvage attempt 44.44 % (4.78)
[34.88, 54.32]
50.91 % (3.89)
[43.02, 58.76]
0.0647 (0.0616)
(−0.0561, 0.1855)
p= 0.2955
Third salvage attempt 26.78 % (5.92)
[15.83, 40.30]
36.99 % (5.65)
[25.97, 49.09]
0.1021 (0.0818)
(−0.0583, 0.2624)
p= 0.2200
Fourth through eighth
salvage attempt
12.31 % (4.07)
[5.47, 22.82]
30.77 % (6.40)
[18.72, 45.10]
0.1846 (0.0759)
(0.0358, 0.3333)
p= 0.0140
CR complete remission, SE standard error
Fig. 2 Estimated 2 year event-free survival for patients who achieved
complete remission after ≥2nd salvage attempt. CR complete remis-
sion, EFS event-free survival
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The pooled data provide important background information
in the outcome of children with multiply R/R B-ALL,
which can be valuable in planning clinical trials assessing
new drugs and biologic agents.
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Table 5 Cox proportional hazards model of event-free survival from start of remission for patients who achieved CR after ≥2 salvage attempts
(n= 108 patients with 125 attempts)
Variable Variable levels Number of
events/total
Univariable analysis Multivariable analysis
HR 95% CI HR 95% CI
Salvage attempt Second 52/82 1.0 – 1.0 –
Third 24/27 1.99 1.21–3.26 1.78 1.06–2.98
Fourth through
eighth
10/16 1.31 0.67–2.60 1.18 0.57–2.44
p-value 0.0323 0.1073
Trend p-value 0.0906 0.1368
Duration of previous
remission
CR not achieved 26/37 0.72 0.40–1.28 0.77 0.40–1.47
CR < 18 m duration 21/29 1.0 – 1.0 –
CR 18–36 m
duration
12/20 0.61 0.30–1.25 0.71 0.34–1.49
CR ≥ 36 m duration 8/16 0.41 0.18–0.92 0.45 0.19–1.04
Not evaluable for
response
19/23 1.16 0.62–2.15 1.20 0.61–2.36
p-value 0.1452 0.2807
Trend p-value 0.1422 0.2211
NCI risk category at
diagnosis
Non-infants,
standard risk
39/60 1.0 – 1.0 –
Non-infants, high
risk
35/46 1.29 0.81–2.02 1.21 0.74–1.97
Non-infants,
unknown
11/17 1.08 0.55–2.11 0.96 0.44–2.11
Infants 1/2 – – – –
p-value 0.7440 0.8127
Extramedullary involvement
at relapse
No 72/101 1.0 – 1.0 –
Yes 14/24 0.67 0.38–1.19 0.71 0.38–1.31
p-value 0.1522 0.2644
Subsequent HSCT No 43/57 1.0 – 1.0 –
Yes 43/68 0.73 0.45–1.21 0.76 0.42–1.36
p-value 0.2292 0.3530
BM status at start of attempt M2 (5–25%) 18/23 1.0 – 1.0 –
M3 (over 25%) 68/102 0.90 0.53–1.51 1.14 0.65–1.99
p-value 0.6854 0.6500
Cytogenetics Favorable 17/24 1.0 – 1.0 –
Unfavorable 14/21 1.02 0.50–2.07 0.53 0.22–1.28
Other 55/80 1.08 0.68–2.03 1.15 0.63–2.10
p-value 0.7802 0.0869
BM bone marrow, CR complete remission, HR hazard ratio, HSCT hematopoietic stem cell transplant. The bold values are the p-values with
statstical signiﬁcance (o 0.05)
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